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Abstract Obesity is a major risk factor for the development
of hypertension. Because the prevalence of obesity is
increasing worldwide, the prevalence of obesity hypertension
is also increasing. Importantly, hypertension in obesity is
commonly complicated by dyslipidemia and type 2 diabetes
mellitus and hence imposes a high cardiovascular disease risk.
Furthermore, obesity is strongly associated with resistant
hypertension. Activation of the sympathetic nervous system
and the renin-angiotensin system, leading to renal sodium and
water retention, links obesity with hypertension. There is also
evidence for the release of factors by visceral adipose tissue
promoting excessive aldosterone production, and a more
central role of aldosterone in obesity hypertension is emerg-
ing. Randomized studies evaluating the effect of different
classes of antihypertensive agents in obesity hypertension are
scarce, short-lasting, and small. Considering the emerging role
of aldosterone in the pathogenesis of obesity hypertension,
mineralocorticoid receptor antagonism may play a more
central role in the pharmacologic treatment of obesity
hypertension in the near future.
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Introduction
Obesity, and especially central obesity, is one of the most
common risk factors for the development of hypertension.
Population studies indicate that two thirds of the prevalence
of hypertension can be attributed to overweight or obesity
[1]. In the National Health and Examination Survey
(NHANES) III, the prevalence of hypertension according
to body mass index (BMI) and adjusted for age was about
14% in participants with a BMI less than 25 kg/m2 versus
about 40% in participants with a BMI greater than 30 kg/m2
[2]. Obesity hypertension is commonly accompanied by
type 2 diabetes mellitus and dyslipidemia [3]. Furthermore,
obesity hypertension is associated with increased risks for
left ventricular hypertrophy, microalbuminuria, and renal
hyperfiltration. Over time, the latter two factors predispose
to impairment of renal function that may further aggravate
hypertension [3].
Obesity is also the most important risk factor for the
syndrome of obstructive sleep apnea (OSA); apart from
obesity itself, OSA also can contribute to the development
and maintenance of hypertension [4]. Finally, obesity and
OSA are well-recognized patient characteristics that, along
with older age, a higher baseline systolic blood pressure,
and left ventricular hypertrophy, are associated with
treatment-resistant hypertension [5, 6].
Obesity Hypertension: The Underlying Mechanism
Obesity hypertension is a complex condition and, as is true
for hypertension in general, impaired pressure natriuresis is
a key etiologic factor [7] (Fig. 1). The renal sodium
retention in obesity hypertension occurs despite an increase
in glomerular filtration rate, indicating increased renal
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fractional tubular sodium reabsorption [8]. Driving forces
for this sodium retention are an increase in renal sympa-
thetic tone and activation of the renin-angiotensin system
(RAS). Moreover, renal medullary compression by exces-
sive adipose tissue, for which we propose the term steatosis
renalis (analogous to steatosis hepatis), may also account
for avid sodium retention [8]. Although renal plasma flow
and glomerular filtration rate are increased in the initial
phase of obesity hypertension to cope with the increased
metabolic demands, glomerular injury contributing to the
maintenance of hypertension is a feared complication in the
long run [9].
Evidence that these mechanisms are involved in
obesity hypertension comes mainly from experimental
studies. Thus the development of obesity-induced hyper-
tension in dogs exposed to a high-fat diet could be
prevented by renal denervation and by agents that
interfere with the renin-angiotensin system [10, 11].
Moreover, in a small clinical study, combined alpha-
adrenergic and beta-adrenergic receptor blockade induced
a greater reduction in blood pressure in obese than in lean
hypertensive patients [12].
Obesity and Resistant Hypertension: The Emerging
Role of Aldosterone
Resistant hypertension is defined as blood pressure that
remains above the target value in spite of the concurrent use
of three antihypertensive agents of different classes. Ideally,
one of the three classes should be a diuretic and all agents
should be prescribed at optimal doses [13]. The prevalence
of resistant hypertension is unknown. In an analysis of
NHANES III, only 53% of the population being treated for
hypertension were controlled to a blood pressure less than
140/90 mm Hg [14]. Blood pressure remains uncontrolled
most often because of persistent elevation of systolic blood
pressure. Patient characteristics associated with resistant
hypertension are older age, obesity, the presence of left
ventricular hypertrophy, and chronic kidney disease [5, 6,
15]. In a large cross-sectional study of 45,125 primary care
patients, those with a BMI of 40 kg/m2 or higher not only
had a higher prevalence of hypertension, but also had a
5.3-fold higher probability of requiring four antihyperten-
sive agents to achieve blood pressure control, compared
with normal-weight patients, and they had a 3.2-fold
probability of requiring three agents [16]. Studies per-
formed in patients with resistant hypertension showed that
the prevalence of primary aldosteronism (PA) is 17% to
22% [17, 18]. Patients with resistant hypertension without
PA had higher plasma aldosterone levels and urinary
aldosterone excretion rates and a larger intravascular
volume than normotensive individuals [19]. The role of
aldosterone in the metabolic syndrome has emerged more
recently. In the Framingham offspring study, higher
aldosterone levels were predictive for the development of
the metabolic syndrome [20]. In blacks, plasma aldoste-
rone, but not plasma renin activity, was higher in
individuals with the metabolic syndrome than in those
without, and a significant association between waist
circumference and plasma aldosterone concentration could
be established [21]. Moreover, weight reduction in obese
individuals results in a decrease in plasma aldosterone
concentration, providing further evidence for a stimulating
effect of adipose tissue on adrenal aldosterone production
[22, 23]. Although several mechanisms may underlie these
higher aldosterone concentrations, one possibility is that it
relates to the secretion of a mineralocorticoid-releasing
factor by adipocytes [24, 25••]. This idea is of interest,
given the concept of angiotensinogen release from adipose
tissue and the documented synergistic action between
aldosterone and angiotensin II [26–28].
Fig. 1 Mechanisms linking
obesity with hypertension
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The beneficial effect of low-dose spironolactone added
to combinations of first-line antihypertensive agents in
patients with resistant hypertension has been shown in
several studies [29, 30•, 31–34]. As shown in Table 1,
almost all patients included in these studies were over-
weight (BMI, 25–30 kg/m2) or obese (BMI >30 kg/m2).
Based on the findings of these studies and the knowledge
that plasma aldosterone is increased in obesity, aldosterone
receptor antagonism seems a logical therapeutic option in
obesity hypertension.
Randomized Trials with Antihypertensive Agents
in Obesity Hypertension
Although obesity-associated hypertension is a highly
prevalent condition, randomized studies evaluating the
effect of specific classes of antihypertensive agents in this
condition are scarce, small, and of short duration. Most of
these studies investigated not only blood pressure reduction
but also the occurrence of potential adverse metabolic
effects. The Treatment in Obese Patients With Hypertension
(TROPHY) trial is the first randomized, double-blind,
placebo-controlled trial comparing the effects of the
angiotensin-converting enzyme (ACE) inhibitor lisinopril
(maximal dose, 40 mg once daily) with hydrochlorothiazide
(HCT, maximal dose 50 mg once daily) in obesity
hypertension [35]. In total, 232 patients (mean age, 52 years)
with a mean BMI of 32 kg/m2 were enrolled. Study
medication was given for 12 weeks. At the end of the study,
office and ambulatory blood pressures were reduced to a
similar extent with both regimens, but the response rate was
not higher than 40% in the lisinopril group and 33% in the
HCT group, in accordance with the knowledge that a
combination of different antihypertensive agents is almost
always required for blood pressure control. Although neither
treatment significantly affected serum insulin or lipid con-
centrations, glucose increased modestly with HCT compared
with lisinopril (difference, 0.5 mmol/L). On the basis of these
findings, the authors concluded that a rational monotherapy
approach for initial treatment of obese patients with hyper-
tension may include an ACE inhibitor or a diuretic.
The CROSS study (Candesartan Role on Obesity and on
Sympathetic System) was published in 2003 [36]. In this
study, which enrolled 127 patients with an average BMI of
33 kg/m2, the effect of candesartan (8–16 mg daily) was
compared with HCT (25–50 mg daily) using a parallel-
group, double-blind study design. Study medication was
given for 12 weeks. Blood pressure reduction with both
regimens was identical, with blood pressure normalization
in about 80% of patients. Compared with HCT, candesartan
was associated with improved insulin sensitivity and
modestly lower muscle sympathetic nerve activity. (It
should be remarked that these two measurements were
performed in only a small fraction of the patients.)
In a third study the effects of valsartan, 160 mg daily,
were compared with those of atenolol, 100 mg daily, in a
double-blind, parallel-group study that included 132
patients with an average BMI of 33 kg/m2 and a waist
circumference of 110 cm [37]. Study medication was given
for 12 weeks. If blood pressure was not normalized after
4 weeks monotherapy with valsartan or atenolol, HCT
(12.5–25 mg daily) could be added. An interesting and
unanticipated finding of this study was that the diastolic
blood pressure reduction was greater with monotherapy
atenolol than with valsartan. HCT was added to 49% of the
patients allocated to atenolol, compared with 70% of the
patients allocated to valsartan. At the end of the treatment
period, blood pressure reduction with the two regimens was
identical. No difference in serum lipids between the two
regimens was observed, whereas in the atenolol group the
homeostasis model assessment (HOMA) insulin index
slightly worsened in insulin-sensitive patients but not in
insulin-resistant patients. The authors concluded that beta-
adrenoceptor blockers and angiotensin II type 1 (AT1)
receptor blockers, particularly in combination with low-dose
Table 1 Summary of studies evaluating the effect of add-on spironolactone treatment in uncontrolled or resistant hypertension
Study Design N BW,
kg
BMI,
kg/m2
Waist
circumference,
cm
Antihypertensives,
n
Spironolactone
dose, mg/day
BP reduction,
mm Hg
Ouzan et al. [32] Uncontrolled 25 NA NA NA 3.2 1 mg/kg 24/10
Saha et al. [33] Placebo-controlled 23 (spironolactone) NA 32.0 NA 2 25 5/2
27 (placebo) NA 35.7 NA 2 – –
Sharabi et al. [34] Uncontrolled 42 NA 30.6 NA ≥2 12.5–25 23.2/12.5
Lane et al. [31] Uncontrolled 119 86.7 NA NA 3.7 25–100 21.7/8.5
Chapman et al. [29] Uncontrolled 1411 29.4 NA ≥3 25–50 21.9/9.5
de Souza et al. [30•] Uncontrolled 175 30.2 100 ≥3 25–100 14/7
BMI body mass index, BW body weight, NA not available
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diuretics, effectively lower blood pressure in obese patients,
but that AT1-receptor blockers may be preferred because of
the high diabetes risk in obesity.
In a more recent study, the direct renin inhibitor aliskiren has
been compared with irbesartan and amlodipine in a placebo-
controlled trial in obese hypertensive patients in whom blood
pressure was still elevated after HCT monotherapy for 4 weeks
[38]. A total of 489 patients with an average BMI of about
34 kg/m2 were included. The mean reduction in blood
pressure in the three active groups was identical. Rates of
blood pressure control were 34% in the HCT group, 57% in
the aliskiren/HCT group, 55% in the irbesartan/HCT group,
and 45% in the amlodipine/HCT group. Adverse effects,
mainly due to a higher incidence of peripheral edema, were
highest in the amlodipine/HCT group.
Although these studies were not performed in patients with
resistant hypertension, they all demonstrate that obesity
hypertension responds to a variety of antihypertensive agents.
As known from many studies in high-risk populations, the
incidence of new-onset diabetes mellitus is increased with the
use of beta-blockers and thiazide diuretics, compared with
other antihypertensive agents [39]. Recently, it was shown
that adverse metabolic effects, including new-onset diabetes,
already occurred after short-term (9–18 weeks) exposure to
atenolol, HCT, or their combination and that this effect was
more common in patients with abdominal obesity [40].
Because the treatment of hypertension usually requires
lifelong therapy and the likelihood of developing adverse
metabolic effects increases with increasing exposure dura-
tion, not only the blood pressure lowering properties but also
the anticipated adverse metabolic effects should be consid-
ered when these agents are prescribed.
Mineralocorticoid Receptor Antagonism in Obesity
Hypertension
In our view, the accumulating evidence of the role of
aldosterone excess in the pathogenesis of obesity hyperten-
sion and the knowledge that mineralocorticoid receptor
blockers promote additional blood pressure reduction in
patients with resistant or difficult-to-control hypertension
provide a firm basis for a more liberal use of spironolactone
(or its more selective counterpart, eplerenone) in obesity
hypertension. In this regard it should be noted that, in the
reported studies on the additional effect of spironolactone in
uncontrolled or resistant hypertension, BMI was 30 kg/m2
or higher in most of the populations studied (Table 1).
Furthermore, a recent prospective study performed in
patients with true resistant hypertension who had an
average BMI of 30 kg/m2 and waist circumference of
100 cm showed in a multivariate regression analysis that a
higher waist circumference and an increased pulse wave
velocity were the two independent variables that predicted
the systolic blood pressure response to spironolactone [30•].
Lifestyle Modification and Interaction
with Antihypertensive Regimens
Without doubt, weight loss and reduction of dietary sodium
intake, although not specifically evaluated in patients with
resistant obesity hypertension, have a clear benefit in reducing
blood pressure and often allow a reduction in the number of
prescribed medications [41, 42••]. A meta-analysis of long-
term weight loss studies indicates that a 10-kg weight loss is
associated with a blood pressure reduction of 6.0 mm Hg
systolic and 4.6 mm Hg diastolic [43]. Therefore, weight
reduction and maintenance of weight loss are important steps
in managing obesity hypertension. Unfortunately, nonphar-
macologic approaches aimed at reducing body weight have
limited sustainability in most patients, and adjuvant pharma-
cotherapy may be necessary for effective weight reduction
and its maintenance [44].
The effectiveness of drug-based weight loss with sibutr-
amine on the basis of different antihypertensive regimens was
addressed in the Hypertension-Obesity-Sibutramine (HOS)
study [45]. In this prospective, double-blind, placebo-
controlled study, 171 patients receiving one of three antihy-
pertensive combination therapies (felodipine plus ramipril,
verapamil plus trandolapril, or metoprolol plus HCT) were
assigned randomly to sibutramine (15mg daily) or placebo for
a period of 16 weeks. Compared with placebo, sibutramine
resulted in a significantly greater decrease in body weight (5.7
vs 1.5 kg), BMI (2.0 vs 0.5 kg/m2) and waist circumference
(5.0 vs 0.8 cm). Remarkably, the sibutramine-induced weight
loss, reduction in BMI, and reduction in waist circumference
were significantly attenuated in the metoprolol plus HCT
group compared with the other two groups. Despite the greater
decrease in body weight, changes in office systolic and
diastolic blood pressure did not differ between the sibutramine
and placebo group. Ambulatory blood pressure recordings for
24 h revealed a small reduction in systolic blood pressure in
both groups (0.3 mm Hg with sibutramine vs 0.9 mm Hg in
the placebo group), but unfortunately an increase in diastolic
blood pressure in the sibutramine group versus placebo (2.1
versus −0.3 mmHg). The smaller decrease in body weight,
BMI, and waist circumference with the use of sibutr-
amine in the patients treated with metoprolol plus HCT
was accompanied by less beneficial effects on glucose
tolerance and hypertriglyceridemia. On the basis of these
findings, the authors concluded that an antihypertensive
combination therapy regimen that is based on ACE
inhibitors and calcium channel blockers is more advan-
tageous than a combination regimen based on diuretics
and beta-blockers in supporting the weight-reduction
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actions and concomitant metabolic changes induced by
sibutramine in obese hypertensive subjects.
Conclusions
Obesity hypertension is a growing condition. In a proportion
of patients with obesity hypertension, the response of blood
pressure to combinations of antihypertensive agents is
insufficient. For these patients, no specific recommendations
or guidelines regarding additional treatment are available. In
light of the emerging role of aldosterone in the pathogenesis of
obesity hypertension and the findings of studies suggesting
that adding a low dose of aldosterone can produce large blood
pressure reductions in patients whose blood pressure is
uncontrolled with conventional antihypertensive treatment,
addition of a mineralocorticoid receptor antagonist as a fourth-
line agent in resistant obesity hypertension is a logical choice.
Conventional or nonvasodilating beta-blockers, although
effective in reducing blood pressure in obesity hypertension,
are not recommended as a first-line, second-line, or third-line
agent because they reduce energy expenditure, lipolysis, and
insulin sensitivity, and a negative interaction with sibutramine
has been documented when they are combined with thiazide
diuretics [45, 46]. The chance of developing diabetes mellitus
is greater with thiazide diuretics than with agents that interfere
with the RAS or with calcium channel blockers [47, 48]. This
negative effect, among others, has been linked with the
reduction in potassium and magnesium levels [49]. This effect
may be less apparent when thiazide diuretics are combined
with anti-RAS agents such as ACE inhibitors or AT1-receptor
blockers or with mineralocorticoid receptor antagonists.
Acknowledgment PMJ is supported by the Dutch Kidney Foundation,
grant C05-2151.
Disclosure No potential conflicts of interest relevant to this article
were reported.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
References
Recently published papers of interest have been highlighted
as:
• Of importance
•• Of major importance
1. Jordan J, Engeli S, Redon J, et al.: European Society of
Hypertension Working Group on Obesity: background, aims and
perspectives. J Hypertens 2007, 25(4):897–900.
2. Brown CD, Higgins M, Donato KA, et al.: Body mass index and
the prevalence of hypertension and dyslipidemia. Obes Res 2000,
8(9):605–619.
3. Sharma AM: Is there a rationale for angiotensin blockade in the
management of obesity hypertension? Hypertension 2004, 44
(1):12–19.
4. Peppard PE, Young T, Palta M, Skatrud J: Prospective study of the
association between sleep-disordered breathing and hypertension.
N Engl J Med 2000, 342(19):1378–1384.
5. Cushman WC, Ford CE, Cutler JA, et al.: Success and predictors
of blood pressure control in diverse North American settings: the
antihypertensive and lipid-lowering treatment to prevent heart
attack trial (ALLHAT). J Clin Hypertens (Greenwich) 2002, 4
(6):393–404.
6. Lloyd-Jones DM, Evans JC, LarsonMG, et al.: Differential control of
systolic and diastolic blood pressure: factors associated with lack of
blood pressure control in the community. Hypertension 2000, 36
(4):594–599.
7. Davy KP, Hall JE: Obesity and hypertension: two epidemics or
one? Am J Physiol Regul Integr Comp Physiol 2004, 286(5):
R803–R813.
8. Hall JE: The kidney, hypertension, and obesity. Hypertension
2003, 41(3 Pt 2):625–633.
9. Bagby SP: Obesity-initiated metabolic syndrome and the kidney:
a recipe for chronic kidney disease? J Am Soc Nephrol 2004, 15
(11):2775–2791.
10. de Paula RB, da Silva AA, Hall JE: Aldosterone antagonism
attenuates obesity-induced hypertension and glomerular hyperfiltra-
tion. Hypertension 2004, 43(1):41–47.
11. Kassab S, Kato T, Wilkins FC, et al.: Renal denervation attenuates
the sodium retention and hypertension associated with obesity.
Hypertension 1995, 25(4 Pt 2):893–897.
12. Wofford MR, Anderson DC Jr, Brown CA, et al.: Antihyper-
tensive effect of alpha- and beta-adrenergic blockade in obese
and lean hypertensive subjects. Am J Hypertens 2001, 14(7 Pt
1):694–698.
13. Calhoun DA, Jones D, Textor S, et al.: Resistant hypertension:
diagnosis, evaluation, and treatment. A scientific statement from
the American Heart Association Professional Education Committee
of the Council for High Blood Pressure Research. Hypertension
2008, 51(6):1403–1419.
14. Hajjar I, Kotchen TA: Trends in prevalence, awareness, treatment,
and control of hypertension in the United States, 1988–2000.
JAMA 2003, 290(2):199–206.
15. Nishizaka MK, Pratt-Ubunama M, Zaman MA, et al.: Validity of
plasma aldosterone-to-renin activity ratio in African American and
white subjects with resistant hypertension. Am J Hypertens 2005,
18(6):805–812.
16. Bramlage P, Pittrow D, Wittchen HU, et al.: Hypertension in
overweight and obese primary care patients is highly prevalent
and poorly controlled. Am J Hypertens 2004, 17(10):904–910.
17. Jansen PM, Boomsma F, van den Meiracker AH, Dutch AI:
Aldosterone-to-renin ratio as a screening test for primary
aldosteronism—the Dutch ARRAT Study. Neth J Med 2008, 66
(5):220–228.
18. Jansen PM, Danser AH, Imholz BP, van den Meiracker AH:
Aldosterone-receptor antagonism in hypertension. J Hypertens
2009, 27(4):680–691.
19. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al.:
Characterization of resistant hypertension: association between
resistant hypertension, aldosterone, and persistent intravascular
volume expansion. Arch Intern Med 2008, 168(11):1159–1164.
20. Ingelsson E, Pencina MJ, Tofler GH, et al.: Multimarker approach
to evaluate the incidence of the metabolic syndrome and
longitudinal changes in metabolic risk factors: the Framingham
Offspring Study. Circulation 2007, 116(9):984–992.
224 Curr Hypertens Rep (2010) 12:220–225
21. Kidambi S, Kotchen JM, Grim CE, et al.: Association of adrenal
steroids with hypertension and the metabolic syndrome in blacks.
Hypertension 2007, 49(3):704–711.
22. Dall’Asta C, Vedani P, Manunta P, et al.: Effect of weight loss
through laparoscopic gastric banding on blood pressure, plasma
renin activity and aldosterone levels in morbid obesity. Nutr
Metab Cardiovasc Dis 2009, 19(2):110–114.
23. TuckML, Sowers J, Dornfeld L, et al.: The effect of weight reduction
on blood pressure, plasma renin activity, and plasma aldosterone
levels in obese patients. N Engl J Med 1981, 304(16):930–933.
24. Goodfriend TL, Calhoun DA: Resistant hypertension, obesity,
sleep apnea, and aldosterone: theory and therapy. Hypertension
2004, 43(3):518–524.
25. •• Sowers JR, Whaley-Connell A, Epstein M: Narrative review:
the emerging clinical implications of the role of aldosterone in the
metabolic syndrome and resistant hypertension. Ann Intern Med
2009, 150(11):776–783. This is an excellent review about
underlying mechanisms and potential links between aldosterone,
insulin resistance, and hypertension.
26. Chai W, Garrelds IM, de Vries R, et al.: Nongenomic effects of
aldosterone in the human heart: interaction with angiotensin II.
Hypertension 2005, 46(4):701–706.
27. Frederich RC Jr, Kahn BB, Peach MJ, Flier JS: Tissue-specific
nutritional regulation of angiotensinogen in adipose tissue.
Hypertension 1992, 19(4):339–344.
28. Massiera F, Bloch-Faure M, Ceiler D, et al.: Adipose
angiotensinogen is involved in adipose tissue growth and
blood pressure regulation. FASEB J 2001, 15(14):2727–2729.
29. Chapman N, Dobson J, Wilson S, et al.: Anglo-Scandinavian
Cardiac Outcomes Trial I: effect of spironolactone on blood
pressure in subjects with resistant hypertension. Hypertension
2007, 49(4):839–845.
30. • de Souza F, Muxfeldt E, Fiszman R, Salles G: Efficacy of
spironolactone therapy in patients with true resistant hypertension.
Hypertension 2010, 55(1):147–152. This study explores the effect
and determinants of antihypertensive response in patients with
true resistant hypertension. In this study, blood pressure was
reduced by 16 and 9 mm Hg with add-on spironolactone therapy,
and controlled ambulatory blood pressure was reached in 48% of
patients. Independent factors associated with better response were
higher waist circumference, lower aortic pulse wave velocity, and
lower serum potassium concentration.
31. Lane DA, Shah S, Beevers DG: Low-dose spironolactone in the
management of resistant hypertension: a surveillance study. J
Hypertens 2007, 25(4):891–894.
32. Ouzan J, Perault C, Lincoff AM, et al.: The role of spironolactone
in the treatment of patients with refractory hypertension. Am J
Hypertens 2002, 15(4 Pt 1):333–339.
33. Saha C, Eckert GJ, Ambrosius WT, et al.: Improvement in blood
pressure with inhibition of the epithelial sodium channel in blacks
with hypertension. Hypertension 2005, 46(3):481–487.
34. Sharabi Y, Adler E, Shamis A, et al.: Efficacy of add-on
aldosterone receptor blocker in uncontrolled hypertension. Am J
Hypertens 2006, 19(7):750–755.
35. Reisin E, Weir MR, Falkner B, et al.: Lisinopril versus
hydrochlorothiazide in obese hypertensive patients: a multicenter
placebo-controlled trial. Treatment in Obese Patients With
Hypertension (TROPHY) Study Group. Hypertension 1997, 30
(1 Pt 1):140–145.
36. Grassi G, Seravalle G, Dell’Oro R, et al.: Comparative effects
of candesartan and hydrochlorothiazide on blood pressure,
insulin sensitivity, and sympathetic drive in obese hypertensive
individuals: results of the CROSS study. J Hypertens 2003, 21
(9):1761–1769.
37. Jordan J, Engeli S, Boschmann M, et al.: Hemodynamic and
metabolic responses to valsartan and atenolol in obese hypertensive
patients. J Hypertens 2005, 23(12):2313–2318.
38. Jordan J, Engeli S, Boye SW, et al.: Direct renin inhibition with
aliskiren in obese patients with arterial hypertension. Hypertension
2007, 49(5):1047–1055.
39. Elliott WJ, Meyer PM: Incident diabetes in clinical trials of
antihypertensive drugs: a network meta-analysis. Lancet 2007,
369(9557):201–207.
40. Cooper-DeHoff RM, Wen S, Beitelshees AL, et al.: Impact of
abdominal obesity on incidence of adverse metabolic effects
associated with antihypertensive medications. Hypertension, 55
(1):61–68.
41. Neter JE, Stam BE, Kok FJ, et al.: Influence of weight reduction
on blood pressure: a meta-analysis of randomized controlled trials.
Hypertension 2003, 42(5):878–884.
42. •• Pimenta E, Gaddam KK, Oparil S, et al.: Effects of dietary
sodium reduction on blood pressure in subjects with resistant
hypertension: results from a randomized trial. Hypertension 2009,
54(3):475–481. This small but elegant study shows that excessive
sodium intake can importantly contribute to resistance to
antihypertensive treatment. The authors conclude that strategies
that substantially reduce dietary salt intake should be part of the
overall treatment of resistant hypertension.
43. Aucott L, Poobalan A, Smith WC, et al.: Effects of weight loss
in overweight/obese individuals and long-term hypertension
outcomes: a systematic review. Hypertension 2005, 45(6):
1035–1041.
44. Haslam DW, James WP: Obesity. Lancet 2005, 366(9492):1197–
1209.
45. Scholze J, Grimm E, Herrmann D, et al.: Optimal treatment of
obesity-related hypertension: the Hypertension-Obesity-Sibutramine
(HOS) study. Circulation 2007, 115(15):1991–1998.
46. Biaggioni I: Should we target the sympathetic nervous system in
the treatment of obesity-associated hypertension? Hypertension
2008, 51(2):168–171.
47. Mason JM, Dickinson HO, Nicolson DJ, et al.: The diabetogenic
potential of thiazide-type diuretic and beta-blocker combinations
in patients with hypertension. J Hypertens 2005, 23(10):1777–
1781.
48. ALLHAT Officers and Coordinators for the ALLHAT Collaborative
Research Group. The Antihypertensive and Lipid-Lowering Treat-
ment to Prevent Heart Attack Trial: Major outcomes in high-risk
hypertensive patients randomized to angiotensin-converting enzyme
inhibitor or calcium channel blocker vs diuretic: The Antihyperten-
sive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
(ALLHAT). JAMA 2002, 288(23):2981–2997.
49. Stump CS, Hamilton MT, Sowers JR: Effect of antihypertensive
agents on the development of type 2 diabetes mellitus. Mayo Clin
Proc 2006, 81(6):796–806.
Curr Hypertens Rep (2010) 12:220–225 225
